170846-74-9

170846-74-9 structure

Name: (R,S)-CHPG
Chemical Name: 2-amino-2-(2-chloro-5-hydroxyphenyl)acetic acid
CAS Number: 170846-74-9
Molecular Formula: C₈H₈ClNO₃
Molecular Weight: 201.60700
Catalog: Signaling Pathways GPCR/G Protein mGluR
Create Date: 2016-11-29 03:33:11
Modify Date: 2024-01-04 02:10:22
CHPG is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells[1]. CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways[2].

Name	2-amino-2-(2-chloro-5-hydroxyphenyl)acetic acid
Synonyms	Pregnanolone CHPG 2-chloro-5-hydroxyphenylglycine

Description	CHPG is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells[1]. CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways[2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> PI3K/Akt/mTOR >> Akt Research Areas >> Inflammation/Immunology Signaling Pathways >> GPCR/G Protein >> mGluR Signaling Pathways >> MAPK/ERK Pathway >> ERK Signaling Pathways >> Stem Cell/Wnt >> ERK
Target	mGluR5 NF-κB ERK Akt
In Vitro	CHPG (10-500 µM; 24 hours) significantly increases the cell viability and decreases the LDH release after SO2 derivatives treatment[1]. CHPG (0.5 mM; 30 mins ) protects BV2 cells against SO2-induced apoptosis[1]. CHPG (0.5 mM; 30 mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels[1]. Cell Viability Assay[1] Cell Line: BV2 microglial cells Concentration: 10, 50, 100 and 500 µM Incubation Time: 24 hours Result: Increased the cell viability. Apoptosis Analysis[1] Cell Line: BV2 microglial cells Concentration: 0.5 mM Incubation Time: 30 mins Result: Protected BV2 cells against SO2-induced apoptosis. Western Blot Analysis[1] Cell Line: BV2 microglial cells Concentration: 0.5 mM Incubation Time: 30 mins Result: Increased the expression of TSG-6 in both mRNA and protein levels.
In Vivo	CHPG (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume[2]. Animal Model: Adult Sprague-Dawley male rats weighing 280-320 g[2] Dosage: 250 nM Administration: Injection; for 7 days Result: Reduced significantly cerebral lesion volume.
References	[1]. Qiu JL, et al. The selective mGluR5 agonist CHPG attenuates SO₂-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. Neurochem Int. 2015 Jun-Jul;85-86:46-52. [2]. Chen T, et al. The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway. Int J Mol Med. 2012 Apr;29(4):630-6.

Molecular Formula	C₈H₈ClNO₃
Molecular Weight	201.60700
Exact Mass	201.01900
PSA	83.55000
LogP	1.83030

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H315-H319-H335
Precautionary Statements	P261-P305 + P351 + P338
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xi
Risk Phrases	R36/37/38
Safety Phrases	S26
RIDADR	NONH for all modes of transport

170846-74-9	359435-41-9
22494-02-6	87305-45-1
863560-23-0	57995-16-1
155830-69-6	1404754-06-8
138651-90-8	87305-44-0